Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Vargatef

Boehringer Ingelheim headquarters

Boehringer’s sales drop after ‘intense and challenging’ year

US operations hit hard by healthcare reforms and insurance consolidation

- PMLiVE

Astellas signs up to immuno-oncology deal

Japanese firm the latest pharma company to buy into the next-gen cancer therapy area

Bristol-Myers Squibb (BMS) building

BMS hails Opdivo and Yervoy combo in melanoma

New PD-1 therapy shines against the world’s first immunotherapy for skin cancer

- PMLiVE

BMS gives Erbitux rights to Lilly in the US

Firm wants to focus on its burgeoning PD-1 cancer range

- PMLiVE

AstraZeneca gains FDA orphan status for new cancer drug

Gains a longer patent life for the investigational lung disease drug

Boehringer Ingelheim headquarters

Boehringer signs renal disease research collaboration

Will work with Hydra Biosciences to identify small-molecule TRP inhibitors

National Institute for Health and Care Excellence NICE logo

UK market access issues put on hold during election

NICE appraisals and Cancer Drugs Fund appeals will not be undertaken until May

- PMLiVE

IQWiG passes Boehringer lung cancer drug

Germany’s cost assessor says it can extend life in some patients, but benefit it ‘minor'

- PMLiVE

US cancer drug prices ‘not rational’

New research from the medical journal JAMA adds to growing pressure over pricing

- PMLiVE

Amgen gets EU nod for wider use of Vectibix

US biotech’s cancer therapy can now be used in a first-line setting

Fighting talk

One thing that grasps my interest is how society has adopted military style language when talking about cancer

Research Partnership

- PMLiVE

The BMJ weighs in on Avastin/Lucentis debate

The UK’s leading medical journal says Avastin should be used for wet AMD to cut costs

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links